Heavy-chain Variable Antibody (VHH) Process Development

• 

  The Development of VHH Antibodies

  Their mission is: one big goal, to solve problems for everyone in the world no matter where you live and what challenges you face. VHH are already ultra powerful and durable in our bodies, but the scientists at Yaohai have been looking into ways on how to make these VHH even stronger for a longer period. This mRNA Plasmid Process Development implies that if successful, VHH-antibody-based therapies would be more effective and patients may require fewer overall treatments. That's crucial because it could reduce the doctor visits needed for people to get care. 

• 

  The Benefits of VHH Antibody Process Developmen

  Though, there are a lot of positives to both creating and applying VHH antibodies. The first is that they are miniscule compared to traditional antibodies, and therefore a lot easier to cook up in a lab. The result may be used to reduce the cost of treatment with VHH antibodies for patients who need them. Affordable treatments would mean more users of the treatment, and quicker recovery. The next benefit of mRNA Purification Process Development is their rapid production. The silver lining however is that, in a world with lots of sick people, having the capacity to manufacture treatments at pace might mean more to go round for all those who could benefit from them. Third, VHH antibodies can be altered to target individual diseases or organs of the body. This indicates that VHH antibody treatments may not only be more effective, but cause fewer side effects — the undesired actions on your body from a medicine — compared to other therapeutics they are derived from.

• 

  The Power of VHH Antibodies

  Unlike FluMab, VHH antibodies provide broad-spectrum disease coverage In fact, they are currently being evaluated as potential therapies and diagnostics against life-threatening conditions — like cancer, diabetes, or even the (in) famous COVID-19 that has plagued many people across the globe. And finally, the Yaohai team is striving to ensure VHH antibodies are safe and efficacious for all those who need them. Scientists are hoping to cure even diseases that were considered impossible with the help of VHH antibodies. That is to say, there is some hope for the millions of people who have suffered with these diseases for so long.

Why choose Yaohai Heavy-chain Variable Antibody (VHH) Process Development?

• Robust Supply Chain & Manufacturing Capabilities

  Yaohai Bio-Pharma, a top 10 manufacturer of biological products, is a specialist in microbial fermentation. We have established an efficient factory that has advanced facilities and robust RD and manufacturing capabilities. Five production lines for drug substances conforming to GMP standards for microbial fermentation and purification along with two fill and final lines for vials and cartridges and pre-filled needles are on offer. The available fermentation scales vary between 100L and Heavy-chain Variable Antibody (VHH) Process Development. Filling specifications for vias are 1ml up to 25ml. the pre-filled cartridge or syringe filling specifications are 1-3ml. The workshop for production is cGMP-compliant and provides that there is a steady supply of commercial and clinical samples. Our facility produces large molecules that are shipped worldwide.

• Customization, Efficiency & Cost-Effectiveness

  Yaohai Bio-Pharma has experience in manufacturing biologics that are created from microorganisms. We offer bespoke RD solutions as well as manufacturing services while minimising potential risks. We have worked with diverse techniques, such as recombinant cellular subunits, vaccines (including peptides), growth factors, hormones, and the Heavy-chain Variable Antibody (VHH) Process Development. We are a specialist in many microorganisms like yeast extracellular and intracellular secretion (yields up to 15g/L) and bacteria intracellular soluble, and inclusion body (yields up to 10g/L). We have also developed a BSL-2 fermentation platform to create bacterial vaccines. We have a track record of improving production processes, thereby increasing yields and reducing costs. We have a highly-efficient technology team to ensure timely and high-quality delivery of projects. This helps us bring your products that are unique faster to the market.

• Professional Expertise & Extensive Experience

  Yaohai Bio-Pharma is a leading in microbial biologics CDMO. Our primary focus is the production of microbial vaccinations and therapeutics for managing pets, human and Heavy-chain Variable Antibody (VHH) Process Development. We are equipped with cutting-edge RD platforms as well as manufacturing technologies that encompass the entire process beginning with the development of microbial strains and cell banking, to method and process development, to clinical and commercial manufacture that ensures the successful supply of new solutions. Through the years, we have accumulated vast knowledge of microbial-based bio processing. Over 200 projects have been successfully completed and we assist our clients to get through regulations, such as those of the US FDA and EU EMA. We also assist them in navigating Australia TGA and China NMPA. We are able respond promptly to market demands and offer tailored CDMO services thanks to our experience and expertise.

• Quality System & Global Regulatory Compliance

  Yaohai BioPharma, a Heavy-chain Variable Antibody (VHH) Process Development Microbial CDMO, integrates regulatory affairs and quality management. We have a quality system that is compliant with current GMP standards, as well as regulations around the globe. Our regulatory team is knowledgeable in global regulatory frameworks to expedite biological launches. We make sure that production processes are traceable, high-quality products, and complying with the rules of the US FDA and EU EMA. Australia TGA and China NMPA is also fulfilled. Yaohai BioPharma has successfully passed the audit on site of the European Union's Qualified Person (QP) to ensure our GMP quality system and production site. We also have passed the initial certification audits of the ISO9001 Quality Management System and ISO14001 Environmental Management System.

Related product categories

• Heavy-chain Variable Antibody (VHH) Process Development
• Single Domain Antibody (sdAb) Process Development
• Antibody-LNP Conjugate Preparation
• HCV Antigen Production
• HCVcAg Manufacturing

Not finding what you're looking for?
Contact our consultants for more available products.